Secure procurement of high-quality autologous and allogeneic starting materials through qualified collection networks.
Maintained chain-of-identity and chain-of-custody controls ensure traceability, compliance, and supply continuity.

GMP-compliant development and manufacturing of autologous and allogeneic T cell and CAR-T therapies.
Closed, scalable platforms with integrated analytics support reproducibility and regulatory readiness.

GMP-grade plasmid DNA manufacturing with optimized fermentation and purification processes.
High-purity, well-characterized material supports clinical development and commercial supply.

Upstream and downstream GMP manufacturing of viral vectors using validated production platforms.
High-titer, high-quality vectors are delivered with analytical control and regulatory alignment.

From comprehensive IND-enabling programs to stand-alone nonclinical studies, our preclinical CRO services provide in vitro and in vivo testing, study design, and regulatory support to evaluate the safety of novel therapeutic candidates and support advancement toward clinical development.

Built on translational expertise, our approach combines smart study design with automation to accelerate progress. We help you overcome challenges quickly and keep your therapy moving toward clinical success.

Establishment and characterization of master and working cell banks under GMP conditions.
Comprehensive testing and documentation ensure traceability, stability, and long-term supply security.

Comprehensive analytical testing to confirm identity, purity, potency, and safety.
Validated, phase-appropriate assays support regulatory submissions and batch release.